NCT00085644View on ClinicalTrials.gov

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

PHASE3CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2004

Study Completion Date

July 31, 2009

Conditions
Ankylosing Spondylitis
Interventions
BIOLOGICAL

adalimumab (D2E7)

Adalimumab 40 mg every other week, subcutaneous

BIOLOGICAL

placebo

Placebo every other week, subcutaneous

Trial Locations (22)

12206

Albany

16635

Duncansville

19611

West Reading

20902

Wheaton

21224

Baltimore

35924

Birmingham

36608

Mobile

46260

Indianapolis

60611

Chicago

68114

Omaha

73112

Oklahoma City

75231

Dallas

77030

Houston

77074

Houston

80230

Denver

80910

Colorado Springs

83706

Boise

84132

Salt Lake City

94143

San Francisco

98104

Seattle

04102

Portland

03756

Lebanon

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00085644 - Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter